

Ramon Colomer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5455397/ramon-colomer-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213 papers	8,755 citations	50 h-index	88 g-index
271 ext. papers	9,775 ext. citations	4.5 avg, IF	5.48 L-index

#	Paper	IF	Citations
213	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022 , 14, 2596	6.6	1
212	Emotional Distress in Cancer Patients During the First Wave of the COVID-19 Pandemic. <i>Frontiers in Psychology</i> , 2021 , 12, 755965	3.4	3
211	Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. <i>Clinical and Translational Oncology</i> , 2021 , 1	3.6	3
210	The Pharmacological or Genetic Blockade of Endogenous Fatty Acid Synthesis Does Not Increase the Uptake of Exogenous Lipids in Ovarian Cancer Cells. <i>Frontiers in Oncology</i> , 2021 , 11, 610885	5.3	4
209	Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , 2021 , 22, 85-97	21.7	24
208	Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours. <i>Clinical and Translational Oncology</i> , 2021 , 23, 1529-1541	3.6	7
207	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021 , 23, 21	8.3	4
206	Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. <i>Onc Immunology</i> , 2020 , 9, 1751548	7.2	12
205	Epigenetic Regulation of Gfi1 in Endocrine-Related Cancers: a Role Regulating Tumor Growth. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
204	Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study 2020 ,		4
203	A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020 , 20, 254-264	3.8	20
202	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. <i>Breast Cancer Research</i> , 2020 , 22, 124	8.3	7
201	When should we order a next generation sequencing test in a patient with cancer?. <i>EClinicalMedicine</i> , 2020 , 25, 100487	11.3	41
200	Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. <i>Scientific Reports</i> , 2020 , 10, 14877	4.9	6
199	A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy 2020 , 8,		13
198	Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. <i>European Journal of Cancer</i> , 2019 , 109, 21-27	7.5	121
197	Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. <i>Breast Cancer Research</i> , 2019 , 21, 69	8.3	10

196	Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e287-e293	3.8	9
195	Nivolumab-induced thyroid dysfunction in patients with lung cancer. <i>Endocrinología y Diabetes y Nutrición (English Ed)</i> , 2019 , 66, 26-34	0.1	0
194	Nivolumab-induced thyroid dysfunction in patients with lung cancer. <i>Endocrinología, Diabetes y Nutrición</i> , 2019 , 66, 26-34	1.3	9
193	Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. <i>Nature Communications</i> , 2019 , 10, 5011	17.4	22
192	BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 72	2.6	0
191	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. <i>Oncotarget</i> , 2019 , 10, 4321-4332	3.3	
190	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019 , 24, 603-611	5.7	20
189	A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2019 , 48, e45-e47	2.6	4
188	Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 197-205	4.4	1
187	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2018 , 20, 815-826	3.6	43
186	Predictors of unknown cancer in patients with ischemic stroke. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 551-557	4.8	16
185	Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. <i>Annals of Oncology</i> , 2018 , 29, 646-653	10.3	74
184	Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival. <i>Annals of Oncology</i> , 2018 , 29, v46	10.3	2
183	Safety of self-expandable metal stents (SEMS) or emergency surgery for acute malignant colonic obstruction in patients treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15505-e15505 ^{2.2}		
182	Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome. <i>Melanoma Research</i> , 2018 , 28, 562-570	3.3	12
181	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. <i>Nature Communications</i> , 2018 , 9, 3501	17.4	26
180	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017 , 53, 79-97	14.4	64
179	Advanced breast cancer clinical nursing curriculum: review and recommendations. <i>Clinical and Translational Oncology</i> , 2017 , 19, 251-260	3.6	6

178	F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 1432-1441	12.9	25
177	P2.02-027 Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S2108-S2109	8.9	5
176	Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells. <i>Oncotarget</i> , 2017 , 8, 11600-11613	3.3	32
175	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017 , 8, 21472-21483	3.3	32
174	Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents. <i>Current Drug Targets</i> , 2017 , 18, 147-159	3	41
173	Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors. <i>Current Drug Targets</i> , 2016 , 17, 1735-1746	3	4
172	Phase I trial of the combination of the multikinase inhibitor nintedanib plus letrozole: A window of opportunity trial in adjuvant hormone-receptor positive breast cancer (HRPBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS615-TPS615	2.2	
171	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEFERT-T Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1557-1564	13.4	168
170	Is Metastatic Disease the Best Setting for Cost-Effectiveness Studies?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3226-7	2.2	2
169	Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. <i>International Journal of Cancer</i> , 2015 , 136, 2078-90	7.5	44
168	Dermatofibrosarcoma Protuberans with Lung Metastasis Requiring Pneumonectomy. <i>Rare Tumors</i> , 2015 , 7, 5981	1.1	2
167	A Fatty Acid Synthase Inhibitor Shows New Anticancer Mechanisms. <i>EBioMedicine</i> , 2015 , 2, 778-779	8.8	4
166	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEFERTT).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 610-610	2.2	3
165	Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer. <i>Oncotarget</i> , 2015 , 6, 7104-22	3.3	12
164	Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial. <i>Molecular Oncology</i> , 2014 , 8, 1719-28	7.9	3
163	Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). <i>British Journal of Cancer</i> , 2014 , 111, 1060-4	8.7	22
162	Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. <i>Clinical and Translational Oncology</i> , 2013 , 15, 477-83	3.6	12
161	Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study. <i>Supportive Care in Cancer</i> , 2013 , 21, 3039-49	3.9	6

160	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet, The</i> , 2013 , 381, 805-16	4.0	1293
159	In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours. <i>British Journal of Cancer</i> , 2013 , 108, 1298-305	8.7	5
158	Dovitinib lactate. <i>Drugs of the Future</i> , 2013 , 38, 81	2.3	2
157	A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. <i>Investigational New Drugs</i> , 2012 , 30, 880-8	4.3	17
156	New synthetic inhibitors of fatty acid synthase with anticancer activity. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 5013-23	8.3	48
155	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , 2012 , 23, 625-631	10.3	93
154	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. <i>European Respiratory Journal</i> , 2011 , 37, 624-31	13.6	256
153	Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico. <i>Revista Española De Patología</i> , 2011 , 44, 32-48	1.2	3
152	A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. <i>Breast Cancer Research</i> , 2011 , 13, R131	8.3	61
151	P198 Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer. <i>Breast</i> , 2011 , 20, S43	3.6	3
150	Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. <i>Supportive Care in Cancer</i> , 2011 , 19, 657-66	3.9	18
149	Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 179-84	3.6	67
148	Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. <i>Clinical and Translational Oncology</i> , 2011 , 13, 636-51	3.6	14
147	3D Assessment of Lymph Nodes vs. RECIST 1.1. <i>Academic Radiology</i> , 2011 , 18, 391-4	4.3	10
146	Prediction of response to targeted therapies in lung cancer using dynamic imaging: still far from clinical implementation. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3716-8; author reply 3718-9	2.2	2
145	Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer. <i>Annals of the New York Academy of Sciences</i> , 2010 , 1210, 86-92	6.5	24
144	Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. <i>Journal of Clinical Oncology</i> , 2010 , 28, 960-6	2.2	31
143	Antimicrobial cyclic decapeptides with anticancer activity. <i>Peptides</i> , 2010 , 31, 2017-26	3.8	19

142	Selection of extreme phenotypes: the role of clinical observation in translational research. <i>Clinical and Translational Oncology</i> , 2010 , 12, 174-80	3.6	22
141	Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , 2010 , 12, 278-86	3.6	2
140	Targeting cytoskeleton reorganisation as antimetastatic treatment. <i>Clinical and Translational Oncology</i> , 2010 , 12, 662-9	3.6	11
139	Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. <i>Clinical Cancer Research</i> , 2009 , 15, 7608-7615	7.5	75
138	Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 351-8	4.4	7
137	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009 , 11, 363-75	3.6	11
136	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009 , 11, 727-36	3.6	2
135	Development of a new questionnaire to assess patient perceptions of cancer-related fatigue: item generation and item reduction. <i>Value in Health</i> , 2009 , 12, 130-8	3.3	14
134	Creatine transporter deficiency in two adult patients with static encephalopathy. <i>Journal of Inherited Metabolic Disease</i> , 2009 , 32 Suppl 1, S91-6	5.4	12
133	Recomendaci3n para la determinaci3n de HER2 en c3ncer de mama. Consenso nacional de la Sociedad Espa3ola de Anatom3a Patol3gica (SEAP) y de la Sociedad Espa3ola de Oncolog3a M3dica (SEOM). <i>Revista Espanola De Patologia</i> , 2009 , 42, 3-16	1.2	3
132	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. <i>Cell Proliferation</i> , 2008 , 41, 59-85	7.9	145
131	Novel chemotherapy approaches in chemoradiation protocols. <i>Gynecologic Oncology</i> , 2008 , 110, S45-8	4.9	10
130	Review of gemcitabine plus taxane combination therapy in the first-line treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 9-12	1.6	1
129	A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 811-6	12.9	104
128	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. <i>Annals of Oncology</i> , 2008 , 19, 420-32	10.3	366
127	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. <i>Annals of Oncology</i> , 2008 , 19, 1097-109	10.3	38
126	Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling 2008 ,		1
125	Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. <i>Breast Cancer Research and Treatment</i> , 2008 , 109, 471-9	4.4	86

124	Giacomo Castelvetro's salads. Anti-HER2 oncogene nutraceuticals since the 17th century?. <i>Clinical and Translational Oncology</i> , 2008 , 10, 30-4	3.6	15
123	Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. <i>Clinical and Translational Oncology</i> , 2008 , 10, 52-7	3.6	7
122	An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value. <i>Clinical and Translational Oncology</i> , 2008 , 10, 219-26	3.6	
121	Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. <i>Clinical and Translational Oncology</i> , 2008 , 10, 367-71	3.6	36
120	BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. <i>Molecular Carcinogenesis</i> , 2008 , 47, 157-63	5	51
119	Her-2/neu-induced "cytokine signature" in breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 617, 311-9	3.6	14
118	Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. <i>Anticancer Research</i> , 2008 , 28, 3671-6	2.3	31
117	High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. <i>Cancer</i> , 2007 , 110, 2178-85	6.4	10
116	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. <i>BMC Cancer</i> , 2007 , 7, 80	4.8	132
115	Current controversies in the management of early breast cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 375-84	3.6	3
114	Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia. <i>Journal of Medical Economics</i> , 2007 , 10, 27-39	2.4	11
113	N-3 fatty acids, cancer and cachexia: a systematic review of the literature. <i>British Journal of Nutrition</i> , 2007 , 97, 823-31	3.6	165
112	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. <i>Oncology Reports</i> , 2007 , 18, 973	3.5	5
111	Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin) by transcriptionally inhibiting HER2 super-expression occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells 2007 , 31, 769		10
110	Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. <i>European Journal of Cancer</i> , 2007 , 43, 144-8	7.5	60
109	Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. <i>European Journal of Cancer</i> , 2007 , 43, 1117-24	7.5	71
108	EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. <i>Neoplasia</i> , 2007 , 9, 614-24	6.4	37
107	Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4613-4613	2.2	28

106	An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). <i>International Journal of Molecular Medicine</i> , 2007 , 20, 3-10	4.4	54
105	Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. <i>International Journal of Oncology</i> , 2007 , 31, 769-76	1	37
104	Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. <i>Oncology Reports</i> , 2007 , 18, 973-80	3.5	35
103	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006 , 8, 193-9	3.6	13
102	Mediterranean diet, olive oil and cancer. <i>Clinical and Translational Oncology</i> , 2006 , 8, 15-21	3.6	80
101	HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". <i>Clinical and Translational Oncology</i> , 2006 , 8, 812-20	3.6	55
100	Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain. <i>Clinical and Translational Oncology</i> , 2006 , 8, 896-902	3.6	7
99	Olive Oil in Cancer Prevention and Progression. <i>Nutrition Reviews</i> , 2006 , 64, 40-52	6.4	6
98	Olive Oil in Cancer Prevention and Progression. <i>Nutrition Reviews</i> , 2006 , 64, S40-S52	6.4	16
97	Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4089-4089	2.2	3
96	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival 2005 , 26, 1507		1
95	What is the best schedule for administration of gemcitabine-taxane?. <i>Cancer Treatment Reviews</i> , 2005 , 31 Suppl 4, S23-8	14.4	14
94	Gemcitabine plus taxane combinations in metastatic breast cancer:a comprehensive review. <i>European Journal of Cancer, Supplement</i> , 2005 , 3, 9-16	1.6	4
93	Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis. <i>Medical Hypotheses</i> , 2005 , 64, 337-41	3.8	22
92	Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?. <i>Medical Hypotheses</i> , 2005 , 64, 342-9	3.8	55
91	Obesity, fatty acid synthase, and cancer: serendipity or forgotten causal linkage?. <i>Molecular Genetics and Metabolism</i> , 2005 , 84, 293-5	3.7	15
90	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. <i>Breast Cancer Research</i> , 2005 , 7, 1	8.3	78
89	Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer. <i>Women's Health</i> , 2005 , 1, 323-9	3	7

88	Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. <i>European Journal of Cancer Prevention</i> , 2005 , 14, 263-70	2	73
87	Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. <i>Annals of Oncology</i> , 2005 , 16, 359-71	10.3	158
86	International conference on the healthy effect of virgin olive oil. <i>European Journal of Clinical Investigation</i> , 2005 , 35, 421-4	4.6	217
85	Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. <i>International Journal of Cancer</i> , 2005 , 115, 19-35	7.5	88
84	Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005 , 24, 291-3	5.3	18
83	Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. <i>Clinical and Translational Oncology</i> , 2005 , 7, 515-7	3.6	37
82	Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1611-5	9.7	30
81	It is not time to stop progesterone receptor testing in breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3868-9; author reply 3869-70	2.2	28
80	Growth and molecular interactions between tamoxifen and trastuzumab. <i>Clinical Cancer Research</i> , 2005 , 11, 3597; author reply 3597-9	12.9	
79	Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3176-3176	2.2	4
78	Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. <i>Drug News and Perspectives</i> , 2005 , 18, 375-85		61
77	The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. <i>International Journal of Oncology</i> , 2005 , 26, 1507-15	1	9
76	Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM). <i>Journal of Clinical Oncology</i> , 2004 , 22, 961-2	2.2	14
75	Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. <i>Annals of Oncology</i> , 2004 , 15, 1719-21	10.3	23
74	Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. <i>Annals of Oncology</i> , 2004 , 15, 201-6	10.3	65
73	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-B 2004 , 24, 591		14
72	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. <i>Annals of Oncology</i> , 2004 , 15, 1749-59	10.3	73
71	Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 10715-20	11.5	264

70	Cancer care in rural areas. <i>British Journal of Cancer</i> , 2004 , 90, 1688; author reply 1689	8.7	
69	Management of metastatic breast cancer: are we prepared to cope with our own success?. <i>British Journal of Cancer</i> , 2004 , 91, 2101; author reply 2102	8.7	
68	Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER-2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). <i>Breast Cancer Research and Treatment</i> , 2004 , 84, 183-95	4.4	63
67	Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2004 , 86, 125-37	4.4	40
66	Dietary interventions in cancer. <i>Clinical and Translational Oncology</i> , 2004 , 6, 496-500	3.6	2
65	Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. <i>Cancer</i> , 2004 , 100, 1833-42	6.4	14
64	Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) is a selective estrogen-response modulator in human breast cancer cells: gamma-linolenic acid antagonizes estrogen receptor-dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human	7.5	20
63	Protocoles Base de gemcitabine et taxanes dans le cancer du sein. <i>American Journal of Cancer</i> , 2004 , 3, 19-20		
62	Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer: a retrospective analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 269-73	2.7	2
61	Omega-6 polyunsaturated fatty acid linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. <i>Oncology Reports</i> , 2004 , 11, 1241	3.5	4
60	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. <i>Journal of Clinical Oncology</i> , 2004 , 22, 507-507	2.2	2
59	Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. <i>Journal of Clinical Oncology</i> , 2004 , 22, 544-544	2.2	15
58	Microarray gene expression analysis of fatty acid synthase (FAS) signaling on breast cancer cell lines. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9690-9690	2.2	2
57	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. <i>Journal of Clinical Oncology</i> , 2004 , 22, 507-507	2.2	3
56	Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. <i>International Journal of Oncology</i> , 2004 , 24, 591-608	1	41
55	Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. <i>Oncology Reports</i> , 2004 , 11, 1241-52	3.5	41
54	Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel	1	25
53	mechanism by which dietary fat can alter mammary tumorigenesis. <i>International Journal of Oncology</i> , 2004 , 24, 585-93 Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. <i>Oncology Reports</i> , 2004 , 12, 411-22	3.5	28

52	Modulation of EGFR and neu expression by n-6 and n-9 high-fat diets in experimental mammary adenocarcinomas. <i>Oncology Reports</i> , 2003 , 10, 1417	3.5	1
51	A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2003 , 4, 286-91	3	6
50	Primary aortic sarcoma with widespread vascular embolic metastases. <i>European Journal of Internal Medicine</i> , 2003 , 14, 258-261	3.9	8
49	CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. <i>Journal of Experimental Medicine</i> , 2003 , 198, 1381-9	16.6	114
48	Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2003 , 14, 783-7	10.3	13
47	Modulation of EGFR and neu expression by n-6 and n-9 high-fat diets in experimental mammary adenocarcinomas. <i>Oncology Reports</i> , 2003 , 10, 1417-24	3.5	26
46	Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2002 , 72, 203-19	4.4	65
45	Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet 2002 , 21, 745		2
44	Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1054-65	9.7	126
43	Does HER-2 status predict only a decreased response to hormone therapy in advanced breast cancer, or does it also predict the extent of metastatic disease?. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4605; author reply 4606	2.2	3
42	Effects of dietary fatty acids on the proliferation, adhesion and metastatic potential of breast cancer cells: an experimental review 2002 , 4, 77-84		
41	Dose intensity and clinical response in head and neck carcinoma treated with cisplatin + 5-fluorouracil 2002 , 4, 485-490		1
40	Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBA-induced mammary tumors compared with a high corn oil diet. <i>International Journal of Oncology</i> , 2002 , 21, 745-53	1	15
39	High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial. <i>Cancer</i> , 2001 , 92, 2508-16	6.4	7
38	High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. <i>Bone Marrow Transplantation</i> , 2001 , 27, 117-23	4.4	2
37	Combined treatment with biphosphonates, low-dose chemotherapy, and trastuzumab in receptor-negative breast cancer patients with bone marrow involvement. <i>European Journal of Internal Medicine</i> , 2001 , 12, 462-463	3.9	1
36	Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. <i>European Journal of Cancer</i> , 2001 , 37, 402-13	7.5	111
35	Prognostic value of cytosolic p53 protein in breast cancer. <i>Tumor Biology</i> , 2001 , 22, 337-44	2.9	13

34	Herceptin: from the bench to the clinic. <i>Cancer Investigation</i> , 2001 , 19, 49-56	2.1	42
33	Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy. <i>Cancer</i> , 2000 , 89, 2169-75	6.4	22
32	Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. <i>Seminars in Oncology</i> , 2000 , 27, 20-4	5.5	7
31	Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. <i>Clinical Cancer Research</i> , 2000 , 6, 2356-62	12.9	104
30	p53 expression in locally advanced pharyngeal squamous cell carcinoma. <i>JAMA Otolaryngology</i> , 1999 , 125, 1356-9		8
29	Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever. <i>Cancer</i> , 1999 , 85, 213-219	6.4	84
28	Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever 1999 , 85, 213		10
27	Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2065-9	2.2	135
26	Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. <i>Journal of Clinical Oncology</i> , 1998 , 16, 1538-46	2.2	52
25	Standard versus high-dose therapy in 10+ breast cancer. <i>Journal of Clinical Oncology</i> , 1998 , 16, 810-1	2.2	2
24	Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. <i>Journal of Clinical Oncology</i> , 1997 , 15, 3178-84	2.2	75
23	Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. <i>British Journal of Cancer</i> , 1997 , 76, 1215-20	8.7	54
22	Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. <i>Endocrinology</i> , 1996 , 137, 4322-30	4.8	35
21	Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. <i>Journal of the National Cancer Institute</i> , 1996 , 88, 1320	9.7	5
20	Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 803-8	9.7	107
19	Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. <i>Cancer</i> , 1995 , 75, 2147-52	6.4	103
18	erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. <i>British Journal of Cancer</i> , 1994 , 70, 819-25	8.7	81
17	Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. <i>Gynecologic Oncology</i> , 1994 , 53, 27-32	4.9	46

16	Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 2287-91	11.5	102
15	Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. <i>Science</i> , 1990 , 249, 1552-5	33.3	266
14	Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. <i>Breast Cancer Research and Treatment</i> , 1989 , 13, 123-33	4.4	79
13	Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. <i>Cancer</i> , 1989 , 64, 1674-81	6.4	95
12	Circulating CA 15-3 antigen levels in non-mammary malignancies. <i>British Journal of Cancer</i> , 1989 , 59, 283-6	8.7	47
11	Mitomycin-C and vinblastine in advanced breast cancer. <i>Oncology</i> , 1989 , 46, 137-42	3.6	14
10	Brain metastases from breast cancer may respond to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 1988 , 12, 83-6	4.4	18
9	Cranial CT scan in transient global amnesia. <i>Acta Neurologica Scandinavica</i> , 1986 , 73, 298-301	3.8	16
8	Myelin basic protein and creatine kinase BB isoenzyme as CSF markers of intracranial tumors and stroke. <i>Acta Neurologica Scandinavica</i> , 1986 , 73, 461-5	3.8	19
7	Serum Ca 15.3 Levels in Patients with Non-Tumoral Diseases, and Establishment of a Threshold for Tumoral Activity. Results in 1219 Patients. <i>International Journal of Biological Markers</i> , 1986 , 1, 159-160	2.8	11
6	Circulating antigen levels in ovarian cancer. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1148-9	2.2	
5	CA 15.3: early results of a new breast cancer marker. <i>Anticancer Research</i> , 1986 , 6, 683-4	2.3	15
4	Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer). <i>Bulletin Du Cancer</i> , 1986 , 73, 94-5	2.4	4
3	Circulating CA 15.3 levels in breast cancer. Our present experience. <i>International Journal of Biological Markers</i> , 1986 , 1, 89-92	2.8	1
2	Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients. <i>International Journal of Biological Markers</i> , 1986 , 1, 159-60	2.8	3
1	Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines		4